Exports of India’s pharmaceutical and meditech sectors are expected to sustain the growth momentum in the ongoing fiscal despite a slowdown in the global economy.
With the government revving up support for drug development in India, as many as 16 blockbuster molecules targeted for a wide range of therapeutic areas, including cancer, diabetes, HIV and tuberculosis, are in the pipeline to be produced in India, Department of Pharmaceuticals, Secretary Arunish Chawla told reporters on the sidelines of CII Pharma and Life Sciences summit.
The Drugs Controller General of India (DCGI) has already granted approvals to some of the molecules, and the government is also now focusing on the upstreams of biological entities, which particularly include basic molecules like amino acids, nucleotides, and vaccine raw materials.
